Nicotine rescue method — Competitive Intelligence Brief

Nicotine rescue method (Nicotine rescue method) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nicotinic acetylcholine receptor agonist. Area: Addiction Medicine / Smoking Cessation.

marketed Nicotinic acetylcholine receptor agonist Nicotinic acetylcholine receptors (α4β2 and other subtypes) Addiction Medicine / Smoking Cessation Small molecule

Target snapshot

Nicotine rescue method (Nicotine rescue method) — VA Office of Research and Development. Nicotine acts as an agonist at nicotinic acetylcholine receptors in the central and peripheral nervous system to reduce cravings and withdrawal symptoms in tobacco dependence.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nicotine rescue method TARGET	Nicotine rescue method	VA Office of Research and Development	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors (α4β2 and other subtypes)
Patch, Nicotine	Patch, Nicotine	Assistance Publique - Hôpitaux de Paris	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors
Nicotine patch - transdermal	Nicotine patch - transdermal	Johns Hopkins University	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors
Motivation-Phase Nicotine Mini-Lozenge	Motivation-Phase Nicotine Mini-Lozenge	VA Office of Research and Development	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors
Nicotine (2 mg)	Nicotine (2 mg)	GlaxoSmithKline	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors
Nicotine Patch and Nicotine Lozenge	Nicotine Patch and Nicotine Lozenge	University of Wisconsin, Madison	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors
Nicotine gum (C)	Nicotine gum (C)	22nd Century Group, Inc.	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nicotinic acetylcholine receptor agonist class)

1. University of Wisconsin, Madison · 3 drugs in this class
2. GlaxoSmithKline · 2 drugs in this class
3. VA Office of Research and Development · 2 drugs in this class
4. Iowa City Veterans Affairs Medical Center · 1 drug in this class
5. Johns Hopkins University · 1 drug in this class
6. Medical University of Vienna · 1 drug in this class
7. 22nd Century Group, Inc. · 1 drug in this class
8. University of Auckland, New Zealand · 1 drug in this class
9. University of California, San Francisco · 1 drug in this class
10. University of Miami · 1 drug in this class